Madeline I Repollet, PhD
Medical Practice at Cp Hl Rd, Fort Washington, PA
License number
Florida 49091
Issued Date
Apr 17, 2017
Effective Date
Apr 17, 2017
Expiration Date
Aug 31, 2018
Category
Health Care
Type
Clinical Laboratory Personnel
Address
Address
2
357 Camp Hill Rd, Fort Washington, PA 19034
3401 Masons Mill Rd SUITE 100, Huntingdon Valley, PA 19006
3401 Masons Mill Rd SUITE 100, Huntingdon Valley, PA 19006
Phone
(215) 740-8826
Professional information
Associate Director, Oncology Laboratory Operations At Veridex
Position:
Associate Director, Oncology Laboratory Operations at Janssen Diagnostics LLC
Location:
Greater Philadelphia Area
Industry:
Medical Devices
Work:
Janssen Diagnostics LLC
- Beerse, Belgium, Huntingdon Valley, PA since Apr 2012
-
Associate Director, Oncology Laboratory Operations
Veridex LLC, a Johnson & Johnson Company
- Huntingdon Valley, PA Sep 2008 - May 2012
-
Lab Operations Manager
Gift of Life Donor Program
- Greater Philadelphia Area Apr 2008 - Sep 2008
-
Quality Affairs Director
Immunicon Corporation
Nov 2005 - Apr 2008
-
Director , Clinical Lab Services
Immunicon Corporation
Sep 1999 - 2005
-
Clinical Research Lab Manager
OB Gyn Diagnostic Lab
1992 - 1995
-
Lab Manager
Unity Hospital
1990 - 1992
-
Cytotechnologist
Minneapolis Medical Research Foundation
1988 - 1990
-
Research Associate
Hospital Regional de Aguadilla
1986 - 1988
-
Cytotechnologist
Education:
Capella University 2011 - 2015
studies towards a PhD in Health Care Administration, Human Services Leadership Michigan State University 2007 - 2009
Certificate, Molecular Lab Diagnostics Temple University 2002 - 2004
MS, QA/RA Temple University 2002 - 2003
Certificate, Clinical Trial Management University of Puerto Rico Medical Sciences Campus 1985 - 1986
Certificate, Cytotechnology Universidad de Puerto Rico 1981 - 1985
BS, Biology
studies towards a PhD in Health Care Administration, Human Services Leadership Michigan State University 2007 - 2009
Certificate, Molecular Lab Diagnostics Temple University 2002 - 2004
MS, QA/RA Temple University 2002 - 2003
Certificate, Clinical Trial Management University of Puerto Rico Medical Sciences Campus 1985 - 1986
Certificate, Cytotechnology Universidad de Puerto Rico 1981 - 1985
BS, Biology
Languages:
Spanish, English, Italian
Analysis Of Circulating Tumor Cells, Fragments, And Debris
US Patent:
2005018, Aug 18, 2005
Filed:
Feb 17, 2004
Appl. No.:
10/780399
Inventors:
Galla Rao - Princeton Junction NJ, US
Christopher Larson - Media PA, US
Madeline Repollet - Fort Washington PA, US
Herman Rutner - Hatboro PA, US
Leon Terstappen - Huntingdon Valley PA, US
Shawn O'Hara - Ambler PA, US
Steven Gross - Ambler PA, US
Christopher Larson - Media PA, US
Madeline Repollet - Fort Washington PA, US
Herman Rutner - Hatboro PA, US
Leon Terstappen - Huntingdon Valley PA, US
Shawn O'Hara - Ambler PA, US
Steven Gross - Ambler PA, US
International Classification:
G01N033/53, G01N033/567, G01N033/574
US Classification:
435007230
Abstract:
The methods and reagents described in this invention are used to analyze circulating tumor cells, clusters, fragments, and debris. Analysis is performed with a number of platforms, including flow cytometry and the CellSpotter® fluorescent microscopy imaging system. Analyzing damaged cells has shown to be important. However, there are two sources of damage: in vivo and in vitro. Damage in vivo occurs by apoptosis, necrosis, or immune response. Damage in vitro occurs during sample acquisition, handling, transport, processing, or analysis. It is therefore desirable to confine, reduce, eliminate, or at least qualify in vitro damage to prevent it from interfering in analysis. Described herein are methods to diagnose, monitor, and screen disease based on circulating rare cells, including malignancy as determined by CTC, clusters, fragments, and debris. Also provided are kits for assaying biological specimens using these methods.
Analysis Of Circulating Tumor Cells, Fragments, And Debris
US Patent:
8329422, Dec 11, 2012
Filed:
Nov 2, 2010
Appl. No.:
12/917630
Inventors:
Galla Chandra Rao - Princeton Jct. NJ, US
Christopher Larson - Springfield PA, US
Madeline Repollet - Fort Washington PA, US
Herman Rutner - Hatboro PA, US
Leon W. M. M. Terstappen - Amsterdam, NL
Shawn Mark O'Hara - Richboro PA, US
Steven Gross - Ambler PA, US
Christopher Larson - Springfield PA, US
Madeline Repollet - Fort Washington PA, US
Herman Rutner - Hatboro PA, US
Leon W. M. M. Terstappen - Amsterdam, NL
Shawn Mark O'Hara - Richboro PA, US
Steven Gross - Ambler PA, US
Assignee:
Veridex LLC - Raritan NJ
International Classification:
G01N 33/574, G01N 33/553, G01N 1/18
US Classification:
435 723, 435 721, 435 724, 435 794, 4352872, 435962, 435523, 435526, 435538, 435 64, 435164, 435175, 435177, 435813, 435824, 435825, 422 73, 422430, 5303888, 5303897, 530413
Abstract:
The methods and reagents described in this invention are used to analyze circulating tumor cells, clusters, fragments, and debris. Analysis is performed with a number of platforms, including flow cytometry and the CELLSPOTTER® fluorescent microscopy imaging system. Analyzing damaged cells has shown to be important. However, there are two sources of damage: in vivo and in vitro. Damage in vivo occurs by apoptosis, necrosis, or immune response. Damage in vitro occurs during sample acquisition, handling, transport, processing, or analysis. It is therefore desirable to confine, reduce, eliminate, or at least qualify in vitro damage to prevent it from interfering in analysis. Described herein are methods to diagnose, monitor, and screen disease based on circulating rare cells, including malignancy as determined by CTC, clusters, fragments, and debris. Also provided are kits for assaying biological specimens using these methods.